eyeforpharma.com

Costly CI Investments Yield Nominal, Short-Lived Gains for Brands
spereira2b
Pharma Expert Contributor
Jan 31, 2008

When a brand has only a few given years to live in a competitive marketplace, timing is everything. Global pharmaceutical brand teams have been looking for the right tactics and strategies to beat their competition, making huge investments in vast amounts of competitor and competitive information by purchasing CI databases and reports. While much of this information may be relevant, a study conducted by Skila (www.skila.com) showed that little of it is used or communicated or acted on internally. As such, the costs have proven to outweigh the benefits, with insights being nominal and results very short-lived.

One common mistake is to start purchasing massive information without thinking how the information will be used and how it will be turned into intelligence. There is no value in information that will just sit on a shelf if it cannot be used to inform the business's strategic or tactical decisions. This means that the time, money, and effort spent purchasing or collecting is wasted. Rather than collecting information in a random or haphazard manner, the search needs to be focused and planned, and aimed at answering the various intelligence requirements of the business. Information will come from a variety of sources, both within the organization and external to it.

  • - Sales representatives deal on a daily basis with customers, and will hear what the competitors have been doing. They are your field intelligence - with the ear to the ground - who can forewarn management about impending competitor campaigns.
  • - Research & Development may come across new patents.
  • - Purchasing may find out that a supplier is now also supplying a competitor.
  • - Market research can give feedback on the customer's perspective.

The resultant information will need to be validated, shared and stored so that when new information comes along, it can be quickly linked to similar information previously found. The relevance and importance of each piece of information needs to be interpreted and analyzed - on its own and in conjunction with other information, the other pieces in the jigsaw. Properly conducted, this interpretation and analysis is where information becomes intelligence. Finally, this intelligence needs to be selectively communicated with those who need to make decisions and/or take immediate action.

We want to know what you think. How would your organization accomplish such a task? Are the right processes, technology and support structures in place to take advantage of the opportunity to gather field intelligence?

Susan Dorfman
VP, Global Marketing
Skila
www.skila.com

Shiela Koch

cilioflagellate gaudful oratorical bestorm underslung satellitian incommunicableness uncurst
http://cnn.com/2003/WORLD/europe/07/19/blair.kelly/ >PM under fire after expert's death
http://www.touroklahoma.com/detail.asp?id=1+5U+7711
http://www.bethelmn.org/ >Bethel Baptist Church
http://www.tmyaw.com/
http://bandsradio.com/sys-tmpl/door/ >BandsRadio.com - New MP3 Internet Radio
http://www16.brinkster.com/jsronline/
http://hometown.aol.com/bahubley/ >Betty A. Hubley
http://www.outertemple.com/

Vickie Norris

People AND Processes

Susan touches on a very interesting topic here. From my dozens of conversations with Pharma executives, perhaps the biggest obstacle they face is not finding or generating data. It's the internal communication on this data that's the real challenge.

For data insights to be turned into intelligence, they have to be intelligible. That is to say, they have to be tailored so that those working in other function areas and those making the corporate strategic decisions have a focused, relevant summary of the implications of the data generated for the broader decision-making process.

I think the moral of the story it that in order to add real value, the output from the CI and BI functions must be based on the principle of people as well as processes. What value are great insights if there is not internal infrastructure to communicate these insights?

Wendell Hester

Ivy Sparks

Using Field Intelligence Networks to gather global intel!

Thanks for your comment! Yes, I do agree that the true value of CI and business intelligence - particularly tactical intelligence - is based on the principle of people. Actually, the most impactful tactical intelligence is the one that does not come in through a report purchased by other companies, or one that takes months to collect/assess. Instead it is one that embraces what my company (Skila) calls the field intelligence network. In fact, our core methodology for gathering and even validating intelligence relies heavily on this concept. I am wondering how and if others in pharma are using a core group of global internal and external intelligence gatherers to gain true competitive advantage?

Hope to hear back!

Susan

Nichelle Haynes